| Purpose | Sentis Hereditary Pancreatic Cancer Test examines 12 genes associated with an increased risk for hereditary Pancreatic Cancer. It includes both well-established Pancreatic cancer susceptibility genes, as well as candidate genes with limited evidence of an association with Pancreatic cancer. Patients identified with hereditary Pancreatic cancer can benefit from increased surveillance and preventative steps to better manage their risk for cancer. Also, if an inherited susceptibility is found, your patient’s family members can be tested to help define their risk.Genes: BRCA2, PALB2, BRCA1, MLH1, MSH2, MSH6, PMS2, PRSS1, SPINK1, ATM, CDKN2A, FANCG |
| Test Code | DX0662 |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | Sentis Hereditary Prostate Cancer - 5mL of peripheral blood OR 2mL of saliva OR ≥3µg good quality DNA
- This test is designed to detect individuals with a germline pathogenic variant, and is not validated to detect mosaicism. It should not be ordered on tumor tissue.
|
| Methodology | - HW2121
- DNA Extraction and QC.
- Targeted Capture of 12 genes associated with Hereditary Pancreatic Cancer.
- Identification of pathogenic mutations in 12 genes associated with Hereditary Pancreatic Cancer.
- Reports having information for targeted drugs (Precision Medicine).
- Genetic Counselling.
|
| Advantages | - All exons plus flanking intronic regions covered for all genes tested (12 genes associated with Hereditary Pancreatic Cancer); one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
- A streamlined sample-to-results workflow with MGI’s platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples.
|
